{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:39:44Z","timestamp":1790145584345,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012546"],"award-info":[{"award-number":["2022A1515012546"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170569"],"award-info":[{"award-number":["82170569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the major talent project training program of the Third Affiliated Hospital of Sun Yat-Sen University","award":["P02089"],"award-info":[{"award-number":["P02089"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to evaluate the diagnostic abilities of the non-invasive serum biomarkers to predict liver fibrosis staging and evaluate the progress of hepatitis B.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We enrolled 433 patients with chronic HBV infection had complete medical data available for the study, who underwent percutaneous liver biopsy. The extent of fibrosis was assessed using the modified METAVIR score. The predictive values of the non-invasive serum biomarkers were evaluated by the areas under the receiving operator characteristics curves (AUROCs) with 95% confidence intervals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The proportion of males with progressive stages of liver fibrosis was relatively larger, and the average age of patients with cirrhosis stages is older than the non-cirrhotic stages. We found PLT, GGT, ALP, TB, FIB4 and GPR to be significantly associated with liver fibrosis in our cohort. GGT showed a sensitivity of 71.4% and specificity of 76.7% in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3), with an AUROC of 0.775 (95%CI 0.711\u20130.840).The AUROCs of the GPR in distinguishing cirrhosis (F4) from non-cirrhotic stages (F1-3) was 0.794 (95%CI 0.734\u20130.853), but it had a lower sensitivity of 59.2%. Additionally, GGT, FIB4, and GPR could differentiate advanced fibrosis (F3-4) from non-advanced fibrosis (F1-2) among individuals with chronic hepatitis B, with AUROCs of 0.723 (95%CI 0.668\u20130.777), 0.729 (95%CI 0.675\u20130.782), and 0.760 (95%CI: 0.709\u20130.811) respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>GGT was a better biomarker to distinguish cirrhosis (F4) from non-cirrhotic stages (F1-3), while GPR was a better biomarker to identify advanced fibrosis (F3-4) and non-advanced fibrosis (F1-2) in patients with chronic hepatitis B.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09465-z","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T08:02:25Z","timestamp":1719388945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The non-invasive serum biomarkers contributes to indicate liver fibrosis staging and evaluate the progress of chronic hepatitis B"],"prefix":"10.1186","volume":"24","author":[{"given":"Shaoxiong","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilun","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"issue":"10161","key":"9465_CR1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"W Seto","year":"2018","unstructured":"Seto W, Lo Y, Pawlotsky J, et al. Chronic hepatitis B virus infection[J]. Lancet. 2018;392(10161):2313\u201324.","journal-title":"Lancet"},{"issue":"1","key":"9465_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hep Intl. 2016;10(1):1\u201398.","journal-title":"Hep Intl"},{"issue":"01","key":"9465_CR3","first-page":"55","volume":"56","author":"K Karkmann","year":"2017","unstructured":"Karkmann K, Piecha F, R\u00fcnzi A, et al. Versorgung Bei Kompensierter Leberzirrhose 2018 \u2013 evidenzbasierte prophylaktische Ma\u00dfnahmen[J]. Z Gastroenterol. 2017;56(01):55\u201369.","journal-title":"Z Gastroenterol"},{"issue":"7","key":"9465_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo AA, Sheth SG, Chopra S. Liver Biopsy[J]. N Engl J Med. 2001;344(7):495\u2013500.","journal-title":"N Engl J Med"},{"key":"9465_CR5","doi-asserted-by":"crossref","unstructured":"Intraobserver. Interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group[J]. Hepatology (Baltimore MD). 1994;20(1):15\u201320.","DOI":"10.1002\/hep.1840200104"},{"key":"9465_CR6","doi-asserted-by":"crossref","unstructured":"G C, M G, A S, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease.[J]. J Hepatol, 2003,39(2):239\u201344.","DOI":"10.1016\/S0168-8278(03)00191-0"},{"issue":"11","key":"9465_CR7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00535-013-0914-y","volume":"49","author":"N Tamaki","year":"2014","unstructured":"Tamaki N, Kurosaki M, Matsuda S, et al. Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients[J]. J Gastroenterol. 2014;49(11):1495\u2013503.","journal-title":"J Gastroenterol"},{"issue":"11","key":"9465_CR8","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/jvh.12563","volume":"23","author":"Q Li","year":"2016","unstructured":"Li Q, Li W, Huang Y, et al. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China[J]. J Viral Hepatitis. 2016;23(11):912\u20139.","journal-title":"J Viral Hepatitis"},{"issue":"7","key":"9465_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/hepr.13333","volume":"49","author":"K Fujita","year":"2019","unstructured":"Fujita K, Oura K, Yoneyama H, et al. Albumin\u2013bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C[J]. Hepatol Res. 2019;49(7):731\u201342.","journal-title":"Hepatol Res"},{"issue":"1","key":"9465_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"EASL-ALEH Clinical Practice Guidelines","year":"2015","unstructured":"EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis.[J]. J Hepatol. 2015;63(1):237\u201364.","journal-title":"J Hepatol"},{"issue":"1","key":"9465_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-016-9760-3","volume":"11","author":"G Shiha","year":"2017","unstructured":"Shiha G, Ibrahim A, Helmy A, et al. Asian-Pacific Association for the study of the liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update[J]. Hep Intl. 2017;11(1):1\u201330.","journal-title":"Hep Intl"},{"issue":"1","key":"9465_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1186\/s12879-019-4459-4","volume":"19","author":"D Huang","year":"2019","unstructured":"Huang D, Lin T, Wang S, et al. The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China[J]. BMC Infect Dis. 2019;19(1):878.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"9465_CR13","first-page":"753","volume":"106","author":"A Stanciu","year":"2002","unstructured":"Stanciu A, Floarea-Strat A. [Knodell and Metavir scoring systems\u2013advantages and limits][J]. Rev Med Chir Soc Med Nat Iasi. 2002;106(4):753\u20136.","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"issue":"2","key":"9465_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C[J]. Hepatology. 1996;24(2):289\u201393.","journal-title":"Hepatology"},{"issue":"6","key":"9465_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection[J]. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"2","key":"9465_CR16","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"C Wai","year":"2003","unstructured":"Wai C. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology. 2003;38(2):518\u201326.","journal-title":"Hepatology"},{"issue":"6","key":"9465_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with Hepatocellular Carcinoma: a New evidence-based Approach\u2014the ALBI Grade[J]. J Clin Oncol. 2015;33(6):550\u20138.","journal-title":"J Clin Oncol"},{"key":"9465_CR18","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.12659\/MSM.918784","volume":"25","author":"X Li","year":"2019","unstructured":"Li X, Xu H, Gao P. Fibrosis index based on 4 factors (FIB-4) predicts liver cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients[J]. Med Sci Monit. 2019;25:7243\u201350.","journal-title":"Med Sci Monit"},{"issue":"7","key":"9465_CR19","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.7863\/jum.2012.31.7.1053","volume":"31","author":"L Xie","year":"2012","unstructured":"Xie L, Chen X, Guo Q, et al. Real-time elastography for diagnosis of Liver Fibrosis in Chronic Hepatitis B[J]. J Ultrasound Med. 2012;31(7):1053\u201360.","journal-title":"J Ultrasound Med"},{"issue":"3","key":"9465_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00535-010-0301-x","volume":"46","author":"H Morikawa","year":"2011","unstructured":"Morikawa H, Fukuda K, Kobayashi S, et al. Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C[J]. J Gastroenterol. 2011;46(3):350\u20138.","journal-title":"J Gastroenterol"},{"issue":"6","key":"9465_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/apt.14219","volume":"46","author":"S Petta","year":"2017","unstructured":"Petta S, Wong VWS, Camm\u00e0 C, et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD[J]. Aliment Pharmacol Ther. 2017;46(6):617\u201327.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"9465_CR22","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1038\/s41598-017-09234-w","volume":"7","author":"R Huang","year":"2017","unstructured":"Huang R, Wang G, Tian C, et al. Gamma-glutamyl-transpeptidase to platelet ratio is not superior to APRI,FIB-4 and RPR for diagnosing liver fibrosis in CHB patients in China[J]. Sci Rep. 2017;7(1):8543.","journal-title":"Sci Rep"},{"issue":"1","key":"9465_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.18632\/aging.104127","volume":"13","author":"M Zhai","year":"2021","unstructured":"Zhai M, Long J, Liu S, et al. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017[J]. Aging. 2021;13(1):279\u2013300.","journal-title":"Aging"},{"issue":"12","key":"9465_CR24","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","volume":"18","author":"AM Moon","year":"2020","unstructured":"Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of Chronic Liver Disease and Cirrhosis[J]. Clin Gastroenterol Hepatol. 2020;18(12):2650\u201366.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"9465_CR25","first-page":"1","volume":"33","author":"ML ZQ","year":"2020","unstructured":"ZQ ML. Burden of cirrhosis and other Chronic Liver diseases caused by specific etiologies in China, 1990\u20132016: findings from the global burden of Disease Study 2016.[J]. Biomed Environ Sci: BES. 2020;33(1):1\u201310.","journal-title":"Biomed Environ Sci: BES"},{"issue":"5B","key":"9465_CR26","doi-asserted-by":"publisher","first-page":"s35","DOI":"10.1053\/jhep.2002.36806","volume":"36","author":"LB Seeff","year":"2002","unstructured":"Seeff LB. Natural history of chronic hepatitis C[J]. Hepatology. 2002;36(5B):s35\u201346.","journal-title":"Hepatology"},{"issue":"2","key":"9465_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","volume":"138","author":"GL Davis","year":"2010","unstructured":"Davis GL, Alter MJ, El Serag H, et al. Aging of Hepatitis C virus (HCV)-Infected persons in the United States: a multiple cohort model of HCV Prevalence and Disease Progression[J]. Gastroenterology. 2010;138(2):513\u201321.","journal-title":"Gastroenterology"},{"issue":"5","key":"9465_CR28","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","volume":"34","author":"P T","year":"2001","unstructured":"T P. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.[J]. J Hepatol. 2001;34(5):730\u20139.","journal-title":"J Hepatol"},{"issue":"2","key":"9465_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"H Thein","year":"2008","unstructured":"Thein H, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression[J]. Hepatology. 2008;48(2):418\u201331.","journal-title":"Hepatology"},{"issue":"4","key":"9465_CR30","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.3892\/mmr.2016.5682","volume":"14","author":"S Xu","year":"2016","unstructured":"Xu S, Li Q, Hu Y, et al. Development of a model based on biochemical, real-time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B[J]. Mol Med Rep. 2016;14(4):3609\u201319.","journal-title":"Mol Med Rep"},{"key":"9465_CR31","doi-asserted-by":"crossref","unstructured":"Lens S, Torres F, Puigvehi M, et al. Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C[J]. Volume 43. Alimentary Pharmacology & Therapeutics; 2016. pp. 364\u201374. 3.","DOI":"10.1111\/apt.13472"},{"issue":"9262","key":"9465_CR32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","volume":"357","author":"F Imbert-Bismut","year":"2001","unstructured":"Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study[J]. Lancet. 2001;357(9262):1069\u201375.","journal-title":"Lancet"},{"issue":"12","key":"9465_CR33","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/carcin\/8.12.1837","volume":"8","author":"AM Edwards","year":"1987","unstructured":"Edwards AM, Lucas CM, Baddams HM. Modulation of \u03b3-glutamyltranspeptidase in normal rat hepatocytes in culture by cell density, epidermal growth factor and agents which alter cell differentiation[J]. Carcinogenesis. 1987;8(12):1837\u201342.","journal-title":"Carcinogenesis"},{"issue":"1","key":"9465_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest[J]. Hepatology. 2007;46(1):32\u20136.","journal-title":"Hepatology"},{"issue":"4","key":"9465_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","volume":"30","author":"BK Kim","year":"2010","unstructured":"Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients[J]. Liver Int. 2010;30(4):546\u201353.","journal-title":"Liver Int"},{"issue":"5","key":"9465_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/jvh.12842","volume":"25","author":"DP Liu","year":"2018","unstructured":"Liu DP, Lu W, Zhang ZQ, et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B[J]. J Viral Hepatitis. 2018;25(5):581\u20139.","journal-title":"J Viral Hepatitis"},{"issue":"8","key":"9465_CR37","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/gutjnl-2015-309260","volume":"65","author":"M Lemoine","year":"2016","unstructured":"Lemoine M, Shimakawa Y, Nayagam S, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut. 2016;65(8):1369\u201376.","journal-title":"Gut"},{"issue":"16","key":"9465_CR38","doi-asserted-by":"publisher","first-page":"e3372","DOI":"10.1097\/MD.0000000000003372","volume":"95","author":"Q Li","year":"2016","unstructured":"Li Q, Song J, Huang Y, et al. The Gamma-Glutamyl-Transpeptidase to platelet ratio does not show advantages than APRI and Fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic Hepatitis B[J]. Medicine. 2016;95(16):e3372.","journal-title":"Medicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09465-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09465-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T08:02:50Z","timestamp":1719388970000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09465-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9465"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09465-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All tissues and medical data were collected with the patients\u2019 and volunteers\u2019 informed consent prior to inclusion in the study, and this study protocol was approved by the Institute Research Ethics Committee of the Third Affiliated Hospitals of Sun Yat-Sen University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"638"}}